HRT Financial’s Immunovant IMVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.8M Buy
331,920
+265,435
+399% +$8.09M 0.02% 665
2026
Q1
$1.65M Sell
66,485
-18,355
-22% -$475K ﹤0.01% 1741
2025
Q4
$2.16M Buy
+84,840
New +$1.89M 0.01% 1253
2024
Q1
– Sell
-92,731
Closed -$3.91M – 2657
2023
Q4
$3.91M Buy
+92,731
New +$3.41M 0.03% 387
2022
Q4
– Sell
-143,690
Closed -$801K – 2776
2022
Q3
$801K Buy
+143,690
New +$702K 0.01% 1070
2022
Q2
– Sell
-92,945
Closed -$512K – 3279
2022
Q1
$512K Buy
92,945
+2,066
+2% +$12.9K ﹤0.01% 1619
2021
Q4
$774K Sell
90,879
-153,002
-63% -$1.26M ﹤0.01% 1344
2021
Q3
$2.12M Buy
243,881
+65,037
+36% +$587K 0.01% 695
2021
Q2
$1.89M Buy
+178,844
New +$2.5M 0.02% 654

Other funds holding IMVT

HRT Financial's IMVT Position: Q2 2026 in Review

HRT Financial increased its Immunovant (IMVT) stake by 399% in Q2 2026, buying an estimated $8.09M and bringing the position to 331,920 shares worth $12.8M. The position accounts for 0.02% of the portfolio, ranked #665.

HRT Financial first reported a position in IMVT in Q2 2021 and has held it in 9 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • HRT Financial held 331,920 shares of Immunovant worth $12.8M as of Q2 2026.
  • HRT Financial bought 265,435 Immunovant shares in Q2 2026, an estimated $8.09M.
  • Immunovant made up 0.02% of HRT Financial's portfolio in Q2 2026, its #665 holding.
  • HRT Financial first reported a position in Immunovant in Q2 2021 and has held it in 9 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.